MarketPeel
Insider Trading Intelligence
Pricing
…
BO

Brendan M. O'malley

ABEO
SVP, GENERAL COUNSEL · ABEONA THERAPEUTICS INC. · CIK 0001884342
FILING MIX · LIFETIME32%/68%
BUYS
11
SELLS
23
TOTAL VALUE
$634.1K
COMPANIES
1
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
440,003
AVG SELL PX
$3.46
TRADE KIND
SHOWING 34 / 34
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Brendan M. O'malley, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+57.14%-0.77%+0.33%-1.10%-3.66%—
14d14+71.43%-4.73%+0.85%-5.58%-8.20%—
30d14+64.29%-6.59%+2.07%-8.66%-4.71%—
60d14+78.57%-18.12%+3.06%-21.17%-20.06%—
90d14+64.29%-20.55%+4.01%-24.56%-12.76%—
180d14(1 pending)+92.31%-14.21%+4.56%-18.78%-32.47%—
1y14(4 pending)+100.00%-24.85%+2.13%-26.98%-50.52%—
2y14(5 pending)+100.00%-15.29%+23.42%-38.72%-71.36%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ABEO · 440,003 shares · as of Jun 9, 2026
0116,178232,356348,534464,71220222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 23 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
6,305$5.30$33.4K440,003Jun 9, 2026Jun 9, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
4,826$5.43$26.2K446,308Jun 8, 2026Jun 9, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
13,578$5.33$72.4K451,134Jan 22, 2026Jan 22, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
113,949——464,712Jan 20, 2026Jan 20, 2026 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
9,366$5.39$50.5K350,763Sep 29, 2025Oct 1, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
688$5.43$3.7K360,129Sep 22, 2025Sep 22, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, Chief Legal Officer
17,428$5.86$102.1K360,817Jul 9, 2025Jul 10, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
10,470$6.76$70.8K378,245Jun 6, 2025Jun 6, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
181$5.24$948388,715Mar 3, 2025Mar 4, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
115,607——388,896Jan 21, 2025Jan 23, 2025 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
6,579$5.89$38.8K273,289Sep 28, 2024Sep 30, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
496$6.02$3.0K279,868Sep 20, 2024Sep 24, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
102,689——280,364Jul 8, 2024Jul 9, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
10,951$4.52$49.5K177,675Jun 5, 2024Jun 7, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASE
SVP, General Counsel
8,600$3.24$27.9K188,718Apr 25, 2024Apr 26, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
92$7.25$667180,026Mar 31, 2024Jun 7, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
183$7.81$1.4K180,118Mar 4, 2024Mar 12, 2024 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
6,557$3.93$25.8K180,301Sep 29, 2023Sep 29, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
563$3.80$2.1K186,858Sep 21, 2023Sep 22, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASE
SVP, General Counsel
3,000$3.80$11.4K187,421Sep 18, 2023Sep 19, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
90,902——184,421Jun 5, 2023Jun 7, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
104$2.82$29393,519Apr 3, 2023Apr 5, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
207$2.28$47293,623Mar 3, 2023Mar 3, 2023 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASE
SVP, General Counsel
5,869$3.13$18.4K93,830Dec 9, 2022Dec 12, 2022 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASE
SVP, General Counsel
7,500$3.99$29.9K87,961Nov 18, 2022Nov 21, 2022 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
72,750——80,461Sep 28, 2022Sep 30, 2022 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
479$3.72$1.8K9,071Sep 21, 2022Sep 22, 2022 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
8,880$0.57$5.0K204,750Dec 6, 2021Dec 8, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
8,880$0.89$7.9K213,630Nov 5, 2021Nov 5, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
25,734$0.90$23.3K222,510Oct 11, 2021Oct 13, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
22,763$1.05$23.9K248,244Oct 8, 2021Oct 8, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
SALE
SVP, General Counsel
2,447$1.05$2.6K271,007Oct 5, 2021Oct 8, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
136,000——273,454Sep 20, 2021Sep 22, 2021 ↗View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
272,000——272,000Sep 20, 2021Sep 22, 2021 ↗View →
Other insiders · ABEO
Loading peer insiders…
About this filer
CIK 0001884342
ROLE
SVP, General Counsel
PRIMARY
ABEO
COMPANIES
1
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001884342DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback